|
Hi JoJo:
I was surprised that no one chose the two year course either and asked the nurse about it.
The people who were in the HERA trial were early stage breast cancer. Most people felt that one year of further treatment was plenty. People want to get on with their lives.
Also, for the contols, a significant number of us are 2+ years out of chemo. (I was the last person enrolled in our trial as a control and I am 1.75 years out) There is a burning question as to whether herceptin will do much good if you are so far out from chemo/diagnosis. Just statistically, without further treatment, if you have had no mets show up your chances of making it are much higher than at initial diagnosis. Based on stats alone, for someone who has survived this long without failure, the best extrapolation/estimate potential benefit of taking Herceptin is about 5%. And that assumes that you belong to the 5% population that might benefit from this course of treatment.
I think that is why no one opted for two years. The estimated potential benefit is too low based on the most optimistic guesswork.
Regards,
Merridith
|